Articles

Is Direct-to-Consumer Advertising for Cancer Drugs Beneficial to Patients?

By Jessica Miller

Health Policy, Policies & Guidelines

October 2016, Vol 7, No 9

DCIS Score Not Cost-Effective in Selecting Patients for Adjuvant Radiation

By Wayne Kuznar

Value in Oncology

October 2016, Vol 7, No 9

Hematologic Cancers Among the Most Costly Malignancies to Treat

By Alice Goodman

Hematologic Cancers, Value in Oncology

October 2016, Vol 7, No 9

Value Assessments of Metastatic Colorectal Cancer Therapies Continue to Focus on Cost

By Charles Bankhead

Value in Oncology

October 2016, Vol 7, No 9

Patient-Reported Outcomes Should Be Used Routinely in Cancer Care

Palliative Care, Personalized Medicine

October 2016, Vol 7, No 9

Death Rates Unaffected by Treatment Choice for Patients with Localized Prostate Cancer

By Alice Goodman

Prostate Cancer, Solid Tumors

October 2016, Vol 7, No 9

No Clear Selection Criteria for Genomic Testing in Patients with Metastatic Colorectal Cancer

By Charles Bankhead

Colorectal Cancer, Solid Tumors

October 2016, Vol 7, No 9

Many Cancer Survivors Have Untreated Depression

By Charles Bankhead

Survivorship, Policies & Guidelines

October 2016, Vol 7, No 9

New Genetic Test May Give Early Warning of Aggressive Prostate Cancers

By Charles Bankhead

Genetic Testing, Personalized Medicine

October 2016, Vol 7, No 9

New Anticancer Drugs Increase Costs but Prolong Life

By Laura Morgan

Value in Oncology

October 2016, Vol 7, No 9

A study by David H. Howard, PhD, Associate Professor, Department of Health Policy and Management, Emory University, Atlanta, and colleagues demonstrated that although anticancer drugs are associated with increased expenses, they were also accompanied by considerable survival benefits across different cancer types (Howard DH, et al. Health Aff [Millwood]. 2016;35:1581-1587)

Page 147 of 329